Sign up Australia
Proactive Investors - Run By Investors For Investors

Idera focuses on cancer drug tilsotolimod after merger with BioCryst fails

Analysts are maintaining a bullish outlook on Idera in the wake of its failed merger with BioCryst
Rob Driscoll of Wedbush is keeping an Outperform rating and a US$3 price target on the stock

Idera Pharmaceuticals (NASDAQ:IDRA) today announced it would focus its efforts on bringing its cancer drug tilsotolimod (IMO-2125) to market following last week’s abrupt end to its merger with BioCryst.

Updates from its phase 2 Illuminate 204 study, which evaluates tilsotolimod’s ability to fight anti-PD 1 refractory melanoma in combination with ipilimumab, are expected.

The results will include topline data from the trial which is set to be unveiled by the middle of next year. A Phase 3 study of the drug as part of the ILLUMINATE-301 trial, is also underway and additional studies are likely.

“Through the body of data we’ve generated to date, as well as from our discussions with our key opinion leader advisors, it has become abundantly clear to us that tilsotolimod has the opportunity to play a more expanded role in the immuno-oncology landscape, particularly in tumor types with limited immunogenicity that have not previously responded well to check-point inhibition approaches,” said Vincent Milano, Idera’s chief executive officer, in a statement.

Read: BioCryst Pharmaceuticals and Idera call it quits on merger

Analysts are maintaining a bullish outlook on Idera in the wake of its failed merger.

Keeping an Outperform rating on the stock and a US$3 price target, Robert Driscoll of Wedbush sees Idera’s current share weakness as a “buying opportunity for patient investors.”

Driscoll cites the strong clinical data presented for tilsotolimod and its upside potential in treating additional cancers as reasons to buy into the stock.

Michael Ulz, a senior research analyst with Baird Equity Research, is just as optimistic and also maintains an Outperform rating and a slightly higher US$4 price target on the stock.

“Overall, we continue to view interim data for tilsotolimod as promising, and with multiple catalysts ahead, we maintain our Outperform rating,” he wrote in a note to investors.

Idera’s merger with BioCryst Pharmaceuticals was killed last week after shareholders in BioCryst voted to torpedo the merger. Nearly 51 million shares of BioCryst were cast against the deal of some 83.4 million shares represented, according to a filing with the Securities and Exchange Commission.

A sizeable number of shareholders of Exton, Pennsylvania-based Idera, meanwhile, backed the merger in its special meeting, which was also held July 10.

Idera and BioCryst had agreed to a merger last January in a bid to combine forces in the battle against rare diseases and focus together on their late-stage clinical trials.

Idera shares were flat at US$1.02 in morning trade today.

View full IDRA profile View Profile

Idera Pharmaceuticals Inc. Timeline

Related Articles

scientist in lab
August 31 2018
While the data bodes well for MTD201, Midatech is most excited by the validation of its Q-Sphera sustained release technology, which it is using in some of its other compounds
Vial of pills
June 25 2018
Cosmos is a modern company, but the trade routes it relies on are ancient
woman at a microscope
August 02 2018
Currently undergoing phase III clinical trials, AP101 is being developed to treat Epidermolysis Bullosa, a condition which occurs prominently in children and makes skin fragile to even the faintest touch

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use